Our research interests are in translational research. We aim at translating the promise of genomic medicine into clinical reality. Current research projects: 1). Identification of novel genes/targets associated with adverse drug reactions and some common multi-factorial diseases such as type II diabetes mellitus, bipolar disorder and Kawasaki disease. 2). Genetics and molecular mechanisms of Stevens-Johnson syndrome, a life-threatening cutaneous adverse drug reaction. We are investigating how the specific HLA allele and the T cell receptor mediating the cell toxicity in causing disseminated keratinocyte death. 3). Improved therapy for Pompe disease, a debilitating, progressive and often fatal myopathy. The enzyme replacement therapy for Pompe disease has dramatically improved the outcome of the disease; however, limitations of the therapy such as neutralizing antibody and variable skeletal response remain a challenge. We are continuing to explore various strategies to improve the therapies.